CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
(131)I-mIBG 治疗复发/难治性神经母细胞瘤：来自未来过去的武器
英文原题：(131)I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past.
查看英文原题
(131)I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
神经母细胞瘤（NB）是儿童最常见的颅外实体瘤，结局差异较大，从自发缓解到高危病例均有；高危病例常复发或难治。约50%的NB患者具有高危特征，尽管接受强化治疗仍常复发或难治，预后较差，长期无事件生存率（EFS）低于10%。利用NB细胞的放射敏感性及去甲肾上腺素转运体（NET）表达，放射性碘标记间碘苄胍（¹³¹I-mIBG）治疗在复发/难治性NB中显示出良好前景。自1985年以来，研究者一直在评估¹³¹I-mIBG的最大耐受剂量和副作用，近期试验则探索其一线治疗应用。本系统综述依据截至2023年12月的MEDLINE、EMBASE和Cochrane CENTRAL数据库文献，评估¹³¹I-mIBG治疗复发/难治性NB的疗效和毒性，并讨论其与CAR-T 细胞、半相合干细胞移植及dinutuximab beta等新兴疗法联合应用的潜在作用。
展开英文摘要原文
Neuroblastoma (NB) is the most common extracranial solid tumor in children, with variable outcomes ranging from spontaneous remission to high-risk cases often leading to relapse or refractory disease.
Approximately 50 % of patients with NB have high-risk features, often experiencing relapse or refractory disease despite intensive treatments and the prognosis remains poor, with long-term event-free survival (EFS) rates below 10 %,Radioactive iodine-labeled meta-iodobenzylguanidine ( I-mIBG) therapy, leveraging NB cells' radiosensitivity and expression of the norepinephrine transporter (NET), has shown promise in treating relapsed or refractory NB.
Since 1985, I-mIBG has been studied to determine the maximum tolerated dose and side effects, with recent trials exploring its use in front-line treatment.
Our systematic review, based on MEDLINE, EMBASE, and Cochrane CENTRAL databases up to December 2023, evaluates the effectiveness and toxicity of I-mIBG therapy in relapsed/refractory NB. It also discusses its potential role in conjunction with emerging therapies like CAR-T cells, haploidentical stem cell transplantation, and dinutuximab beta.
论文信息
- 作者
- Fabozzi F、Villani MF、Del Bufalo F、Altini C、Cannatà V、Davide C、Pizzoferro M、Drago M
- 第一作者单位
- Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.Italy
- 通讯作者单位
- Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: mantonietta.deioris@opbg.net.Italy
- 文献类型
- 系统综述
- 期刊
- Critical reviews in oncology/hematology2025 Mar
- 原文标识
- PubMed 39732302 · DOI 10.1016/j.critrevonc.2024.104606